Protein Kinase Inhibitors: all 15,278 studies that test it

Page 91 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Active, not recruitingNCT04590235Phase 1
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
• Cabozantinib in Hepatocellular CarcinomaActive, not recruitingNCT04588051Phase 2
• Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsCompletedNCT04587713Phase 1
• Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.TerminatedNCT04586335Phase 1
• A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor CancerTerminatedNCT04586270Phase 1
• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586023Phase 3
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586010Phase 3
• Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnNCT04585724Phase 1
• PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingNCT04584853Phase 3
• A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsActive, not recruitingNCT04584710Phase 2
• Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerStatus unknownNCT04582981Phase 2
• Efficacy and Safety of Sirolimus in Active Systemic Lupus ErythematosusActive, not recruitingNCT04582136Phase 3
• Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedNCT04581954Phase 1/2
• Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release FormulationsCompletedNCT04580797Phase 1
• A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
• First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid TumorsCompletedNCT04577703Phase 1
• A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788WithdrawnNCT04576208Phase 2
• IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)TerminatedNCT04575610Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerCompletedNCT04574284Phase 2
• Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingNCT04572763Phase 1/2
• Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerStatus unknownNCT04572542Phase 1/2
• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1
• A Trial of SHR1258 in Patients With Biliary Tract CancerWithdrawnNCT04571710Phase 2
• Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
• Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04566887Phase 2
• A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsCompletedNCT04565574Phase 1
• Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCActive, not recruitingNCT04565054Phase 3
• A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
• Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedNCT04563871Phase 2
• NPC - AXEL Study : Axitinib-AvelumabCompletedNCT04562441Phase 2
• To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian CancerWithdrawnNCT04561817Phase 2
• Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
• TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
• Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid CancerCompletedNCT04557306Phase 1
• Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 1
• Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLTerminatedNCT04554459Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
• A Study of JNJ-64251330 in Healthy ParticipantsCompletedNCT04552197Phase 1
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
• Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingNCT04551495Phase 2
• Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaActive, not recruitingNCT04551430Phase 2
• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisActive, not recruitingNCT04551131Phase 1/2
• NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ TumorsStatus unknownNCT04550663Phase 1
• Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract CarcinomaCompletedNCT04550624Phase 2
• Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed ConditionCompletedNCT04549480Phase 1
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP RegimenStatus unknownNCT04547855Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
• Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingNCT04544449Phase 3
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04544189Phase 2
• The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation RecipientActive, not recruitingNCT04542733Not applicable
• Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished ChildrenStatus unknownNCT04542473Phase 2/3
• Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseCompletedNCT04541407Phase 1
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTerminatedNCT04541225Phase 1
• A Phase I/II Study of XZP-3287 in Metastasis Solid TumorsActive, not recruitingNCT04539496Phase 1/2
• A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04536961Phase 1
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerCompletedNCT04534218Phase 2
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingNCT04533750Phase 1
• Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Active, not recruitingNCT04533581Phase 2
• A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell CarcinomaStatus unknownNCT04533321Phase 2
• A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedNCT04530981Phase 1
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
• Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedNCT04528667Phase 2
• ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingNCT04526782Phase 2
• Alpelisib and Paclitaxel in PIK3CA-altered Gastric CancerStatus unknownNCT04526470Phase 1/2
• REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid TumorsCompletedNCT04526106Phase 1/2
• Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II StudyStatus unknownNCT04524884Phase 2
• A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Active, not recruitingNCT04524208Phase 2
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04524000Phase 2
• Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver FunctionCompletedNCT04522908Phase 2
• PRECISE CURATE.AI Pilot Clinical TrialStatus unknownNCT04522284Phase 1/2
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
• Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease ParticipantsCompletedNCT04520451Phase 2
• A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)Active, not recruitingNCT04520269Phase 1/2
• Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIsStatus unknownNCT04519983Phase 2
• TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT04518345Early Phase 1
• A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)TerminatedNCT04518137Phase 2
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
• Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) SubjectsTerminatedNCT04515979Phase 2
• Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy ParticipantsCompletedNCT04515628Phase 1
• Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
• Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS LymphomaStatus unknownNCT04514393Phase 2
• A Study of ZN-c5 and Abemaciclib in Participants With Breast CancerCompletedNCT04514159Phase 1
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
• A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).CompletedNCT04511845Phase 1
• Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentCompletedNCT04511455Phase 2
• Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKITerminatedNCT04510415Phase 1
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
• Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and ChemoradiotherapyStatus unknownNCT04507035Phase 4
• Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT04505254Phase 2

← Protein Kinase Inhibitors overview